/Waters%20Corporation%20on%20the%20screen%20of%20an%20exchange_By%20maurice%20norbert.jpeg)
Milford, Massachusetts-based Waters Corporation (WAT) provides analytical workflow solutions. With a market cap of $41.1 billion, the company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and Waters perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the diagnostics & research industry. The leading player in liquid chromatography and mass spectrometry's focus on innovation through substantial R&D investment drives new product development. With a diverse customer base spanning biopharmaceutical, industrial, and academic/government sectors, WAT maintains a stable revenue stream and capitalizes on growth opportunities across multiple industries.
Despite its notable strength, WAT shares touched their 52-week high of $431.78 in the last trading session. Over the past three months, WAT stock has gained 20.4%, outperforming the State Street Health Care Select Sector SPDR ETF’s (XLV) 12% gains during the same time frame.
Shares of WAT rose 13.1% on a YTD basis and climbed 41.5% over the past 52 weeks, outperforming XLV’s YTD gains of 9.1% and 23% returns over the last year.
To confirm the bullish trend, WAT has been trading above its 50-day moving average since mid-April, experiencing some fluctuations. The stock has been trading above its 200-day moving average since early May, with slight fluctuations.
WAT outperformed on strong demand for lab equipment, chemicals and routine testing supplies with double-digit growth, plus momentum from its Biosciences & Diagnostics acquisitions. CEO Udit Batra cited broad-based pharma, academic, and government demand, with GLP-1 testing up over 40%, driven by new launches like Cyclic IMS P20 and Xevo MRT P10 and a successful 180-day revitalization of acquired assets. Pricing actions and $75 million cost savings are supporting margins, while replacement cycles and U.S. pharma reshoring provide forward tailwinds.
WAT’s rival, Agilent Technologies, Inc. (A) lagged behind the stock, with 23.4% gains over the past 52 weeks, but outpaced the stock with a 14.9% uptick on a YTD basis.
Wall Street analysts are reasonably bullish on WAT’s prospects. The stock has a consensus “Moderate Buy” rating from the 24 analysts covering it, and the mean price target of $444.83 suggests a potential 3.5% upside from current price levels.
